GT Biopharma (FRA:OXIA) Buyback Yield %: 0.00 (As of Jul. 11, 2026)


FRA:OXIA GT Biopharma Inc FRA:OXIA
28 GF Score
Price €4.77
! 1 Warning Sign
View Full Analysis

What is GT Biopharma Buyback Yield %?

GT Biopharma FRA:OXIA 28 Buyback Yield % is 0.00 as of Jul. 11, 2026. GuruFocus rates FRA:OXIA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 742 Biotechnology companies, GT Biopharma ranks worse than 134770.75% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

GT Biopharma's current buyback yield was 0.00%.

GT Biopharma Buyback Yield % Historical Data

* Premium members only.

The historical data trend for GT Biopharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GT Biopharma Buyback Yield % Chart

GT Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.86 0.72 -61.94 -26.67 0.00

GT Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:OXIA vs INTI, HIND, TPST: Buyback Yield % Comparison

For the Biotechnology subindustry, GT Biopharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GT Biopharma Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Buyback Yield % falls into.


FRA:OXIA
28GF Score
GT Biopharma Inc FRA:OXIA
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

GT Biopharma's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 121.79718
=0.00%

GT Biopharma's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 167.81814
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
GT Biopharma (FRA:OXIA) has a Buyback Yield % of 0.00 as of Jul. 11, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on GT Biopharma and its competitors. According to the industry distribution chart, GT Biopharma ranks #999999 out of 742 companies in the Biotechnology industry.
Is GT Biopharma's Buyback Yield % too high?
GT Biopharma's current Buyback Yield % is 0.00. Based on the distribution chart, GT Biopharma ranks #999999 out of 742 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GT Biopharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does GT Biopharma's Buyback Yield % compare to INTI and HIND?
According to the Biotechnology industry distribution chart, GT Biopharma ranks #999999 out of 742 companies for Buyback Yield %. This places GT Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on GT Biopharma and its competitors. GT Biopharma's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GT Biopharma stock overvalued right now?
GT Biopharma (FRA:OXIA) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. GT Biopharma's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For GT Biopharma (FRA:OXIA), the current Buyback Yield % is 0.00 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GT Biopharma Business Description

Other Exchanges GTBP:USA
Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
28GF Score

Get the complete analysis for FRA:OXIA

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.77
Price